Novartis is building a new radioligand plant in China
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya. Today, we explore how traditionally underserved sickle cell patients became early recipients of a futuristic gene-editing therapy, see another generative AI drug discovery deal forged, and more.
Read Original Article: Novartis is building a new radioligand plant in China »
